Antibacterial Prophylaxis vs no Prophylaxis for Hematological Malignancies Patients Before Allo-HSCT
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative
treatment for a variety of hematologic malignancies. Bacterial infections remain a common
complication of allo-HSCT, especially in the pre-engraftment phase. Pre-engraftment
neutropenia typically lasts for up to 2 weeks in autologous HSCT but is considerably longer
in allogeneic HSCT recipients who receive myeloablative conditioning regimens. This is a
prospective, randomized, controlled, phase II/III clinical trial that aims to investigate the
beneficial and harmful effects of prophylactic use of imipenem in patients with hematological
malignancies before allo-HSCT. All patients aged above 14 years, diagnosed with hematological
malignancies and ready to undergo allo-HSCT, no active infection within 3 weeks before
allo-HSCT, with a normal CT scan-chest before entering the transplantation cabin and willing
to participate in the trial will be enrolled.